SAN DIEGO / Apr 03, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report. This report provides updates on key corporate sustainability initiatives that are aligned with Dexcom’s core values and business strategy.
“We are always working to advance the interests of our stakeholders, including our global customer base, employees and their families, caregivers, our communities, and our shareholders,” said Kevin Sayer, chairman, president and CEO of Dexcom. “We see an inherent connection between sustainability and strategy and look forward to continuing to drive advances in global health through access to Dexcom CGM technology.”
Dexcom’s sustainability initiatives are integrated as foundational elements of the company’s core values and business strategy. The sustainability report is once again framed according to the company’s four core values: Listen, Think Big, Be Dependable, and Serve with Integrity.
Highlights from this year’s report include:
Dexcom’s annual Sustainability Report can be found on the company’s investor relations site at investors.dexcom.com. All data in the report reflects fiscal year 2023, unless noted otherwise.
About DexCom, Inc.
DexCom, Inc. empowers people to take control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.
Last Trade: | US$70.48 |
Daily Change: | -1.32 -1.84 |
Daily Volume: | 3,936,510 |
Market Cap: | US$28.240B |
October 24, 2024 September 04, 2024 August 28, 2024 August 26, 2024 August 14, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB